There are 3161 resources available
151P - Enhanced pharmacodynamic effects upon combination of cibisatamab and FAP-4-1BBL in 3L+ mMSS CRC patients
Presenter: Ignacio Melero
Session: Poster session 08
152P - Exploratory biomarker analysis of phase III ASTRUM-004 study: Serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer
Presenter: Caicun Zhou
Session: Poster session 08
153P - 23ME-01473, an Fc-enhanced anti-ULBP6/2/5 antibody, restores anti-tumor NK cell function through NKG2D and FcgRIIIa activation
Presenter: Kim Gerrick
Session: Poster session 08
154P - Phase II study of nivolumab and relatlimab utilizing single cell analysis of circulating T cells reveals immune features associated with response to dual PD-1 and LAG-3 inhibition
Presenter: James Dollar
Session: Poster session 08
155P - The molecular basis of the lymphocyte stability index (LSI): A pan-cancer peripheral biomarker for survival post immune checkpoint blockade (ICB)
Presenter: Robert Watson
Session: Poster session 08
156P - Microbiota-related multiomics to assess the clinical relevance of antibiotics (ATB) in immunotherapy (ICI)
Presenter: Adele Bonato
Session: Poster session 08
157P - Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy
Presenter: Joao Gorgulho
Session: Poster session 08
158P - Patterns of immune-related adverse events in early-phase cancer immunotherapy trials
Presenter: Benjamin Fairfax
Session: Poster session 08
160P - Predicting immune-related adverse events using biomarkers in early-phase cancer immunotherapy trials
Presenter: Benjamin Fairfax
Session: Poster session 08